Novartis unveils new data advancing prostate, breast cancer and hematology treatments at ASCO and EHA 2026.

Novartis presented over 65 abstracts at the 2026 ASCO and EHA meetings, highlighting new data on its radioligand therapy Pluvicto for prostate cancer, Kisqali for breast cancer, and Scemblix for chronic myeloid leukemia. The data reinforce Novartis' leadership in oncology with promising efficacy and safety results, including long-term outcomes and biomarker insights. Upcoming presentations will further detail novel therapies like ianalumab for immune thrombocytopenia and actinium-based radioligand therapy, underscoring Novartis' commitment to innovative cancer treatments.